Spark Therapeutics Inc (NASDAQ:ONCE) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 3,782 call options on the stock. This is an increase of approximately 2,582% compared to the typical daily volume of 141 call options.
Spark Therapeutics (NASDAQ ONCE) opened at $45.21 on Friday. Spark Therapeutics has a fifty-two week low of $41.06 and a fifty-two week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. Spark Therapeutics’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.07) earnings per share. analysts predict that Spark Therapeutics will post -7.6 earnings per share for the current year.
In related news, insider Daniel Faga sold 1,500 shares of Spark Therapeutics stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the transaction, the insider now owns 1,500 shares of the company’s stock, valued at approximately $127,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jeffrey D. Marrazzo sold 20,000 shares of Spark Therapeutics stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the transaction, the chief executive officer now directly owns 250,000 shares in the company, valued at approximately $17,885,000. The disclosure for this sale can be found here. Insiders have sold a total of 1,068,809 shares of company stock worth $89,809,385 in the last three months. 7.30% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. boosted its position in Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the period. Vanguard Group Inc. boosted its position in Spark Therapeutics by 5.3% during the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock worth $114,968,000 after purchasing an additional 96,803 shares during the period. JPMorgan Chase & Co. boosted its position in Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares during the period. Janus Henderson Group PLC boosted its position in Spark Therapeutics by 46.4% during the third quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock worth $67,413,000 after purchasing an additional 239,723 shares during the period. Finally, Orbimed Advisors LLC bought a new position in Spark Therapeutics during the third quarter worth $38,340,000. Institutional investors and hedge funds own 94.94% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.